REG - Sareum Holdings PLC - Phase 1a clinical trial for SDC-1801

Sareum HoldingsAnnouncement

18/05/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230518:nRSR8615Za&default-theme=true

RNS Number : 8615Z  Sareum Holdings PLC  18 May 2023

 Sareum Holdings PLC

("Sareum" or the "Company")

Sareum announces the commencement of a Phase 1a clinical trial for SDC-1801

Cambridge, UK, 18 May 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, today announces the initiation of a Phase 1a
clinical trial for its lead product SDC-1801. The trial has started with
patient recruitment in progress at specialist clinical units located in
Victoria, Australia.

SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new
therapeutic for a range of autoimmune diseases with an initial focus on
psoriasis, an autoimmune condition affecting the skin.

This follows the recent approval
(https://otp.tools.investis.com/clients/uk/sareum_holdings_plc/rns/regulatory-story.aspx?cid=2841&newsid=1685844)
of the Company's application under the Clinical Trial Notification (CTN)
scheme by the Human Research Ethics Committee (HREC). Australia's medicines
regulator, the Therapeutic Goods Administration (TGA), has also acknowledged
the application, allowing for the Phase 1a trial to proceed.

The initial Phase 1a trial is designed to investigate the safety and
pharmacokinetics of an oral formulation of SDC-1801 in healthy subjects (trial
ID ACTRN12623000416695p). Provided satisfactory safety data are obtained from
this initial study, a Phase 1b clinical study is expected to commence in
psoriasis patients in 2024.

-Ends-

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Lauren Williams, Head of Investor Relations         ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Oliver Duckworth                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   020 3709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGUGDURUBDGXI